Cardiometabolic Disorders News

In 2024, there were numerous trials and a few regulatory moves related to advancements in lipid management for the prevention of major adverse CV events.

Use of SGLT2 inhibitors was associated with improved kidney health among a diverse multiethnic cohort of Asian adults with type 2 diabetes, researchers found in a retrospective cohort study.

High genetically predicted LDL was inversely associated with risk for incident diabetes, whereas the opposite trend was observed for CAD risk, researchers reported.

Midlife women with a metabolic dysfunction-associated steatotic liver disease diagnosis were more likely to report severe or very severe hot flashes, though researchers found no direct link between the two conditions, data show.

Obesity is an important health issue for patients with chronic kidney disease, speeding its progression, contributing to disability and limiting access to organ transplantation. Up to now, nephrologists typically do not manage obesity.

For the second time since 2019, the oral SGLT1 and SGLT2 dual inhibitor sotagliflozin has been denied FDA approval for adults with type 1 diabetes, with elevated risk for diabetic ketoacidosis being a primary concern.

New findings on semaglutide and tirzepatide published in 2024 revealed that the medications may have benefits beyond lowering glucose levels and body weight.

Maridebart cafraglutide, a novel injectable GLP-1 receptor agonist/GIP receptor antagonist, reduced body weight by up to approximately 20% at 1 year in patients with overweight or obesity without a weight loss plateau, according to a presentation.

The health benefits of time-restricted eating go beyond weight loss and may be most prominent in patients already with cardiometabolic syndrome at baseline, a speaker reported.